A importância do plasma convalescente e/ou globulina hiperimune em pacientes com doença coronavírus 2019 (Covid-19) / The importance of convalescent plasma and/or hyperimmune globulin in patients with coronavirus disease 2019 (Covid-19)
DOI:
https://doi.org/10.34119/bjhrv4n5-344Keywords:
COVID-19, Plasma Convalescente e Globulina Hiperimune, Síndrome Respiratória Aguda Grave.Abstract
O presente aparecimento da doença coronavírus 2019 (COVID-19) resultou em uma crise global. Visto que, para várias doenças virais os medicamentos são restritos e as vacinas não estão com 100% de eficácia, essa revisão de literatura retrata a importância da eficácia do plasma convalescente ou globulina hiperimune em pacientes com COVID-19, abordado na base de estudos apresentados até o momento. Os bancos de dados PubMed (National Library of Medicine), SCIELO (Scientific Eletronic Library online-Brasil), UPTODATE e AERZTEBLATT.DE, pesquisado de 2005 a 2021. Além disso, inclui os resultados e doses nos pacientes oferecendo um tratamento promissor pelo plasma convalescente na COVID-19. Com isso, devido à falta de informação da moléstia atual, essa revisão de literatura de caráter exploratório e abordagem qualitativa aborda sobre a importância do plasma convalescente.
References
- Ahn, Jin Young, et al. “Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea”. Journal of Korean Medical Science, vol. 35, no 14, abril de 2020, p. e149. PubMed Central, https://doi.org/10.3346/jkms.2020.35.e149.
- Ärzteblatt, Deutscher Ärzteverlag GmbH, Redaktion Deutsches. “Behandlung von COVID-19 mit Rekonvaleszentenplasma:...” Deutsches Ärzteblatt, 9 de julho de 2021, https://www.aerzteblatt.de/nachrichten/125459/Behandlung-von-COVID-19-mit-Rekonvaleszentenplasma-Uneinheitliche-Studienlage-erschwert-die-Bewertung.
- Ärzteblatt, Deutscher Ärzteverlag GmbH, Redaktion Deutsches. “Rekonvaleszentenplasma soll bei schweren COVID-19-Verläufen...” Deutsches Ärzteblatt, 8 de abril de 2020, https://www.aerzteblatt.de/nachrichten/111807/Rekonvaleszentenplasma-soll-bei-schweren-COVID-19-Verlaeufen-helfen.
- Bloch, Evan M., et al. “Deployment of convalescent plasma for the prevention and treatment of COVID-19”. The Journal of Clinical Investigation, vol. 130, no 6, p. 2757–65. PubMed Central, https://doi.org/10.1172/JCI138745.
- Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020 Jun;59(3):102790. doi: 10.1016/j.transci.2020.102790. Epub 2020 Apr 20. PMID: 32345485; PMCID: PMC7194745.
- Casadevall, A., e M. D. Scharff. “Serum therapy revisited: animal models of infection and development of passive antibody therapy.” Antimicrobial Agents and Chemotherapy, vol. 38, no 8, agosto de 1994, p. 1695–702.
- Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474–478. doi: 10.1016/S1471-4906(03)00228-X.
- Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. doi: 10.1007/s10096-004-1271-9. PMID: 15616839; PMCID: PMC7088355.
- “NIH Halts Trial of COVID-19 Convalescent Plasma in Emergency Department Patients with Mild Symptoms”. National Institutes of Health (NIH), 2 de março de 2021, https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms.
- OLIVEIRA, Fernando Anselmo de et al. Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results. Einstein (São Paulo), v. 19, 2021.
- “OMS pede cautela com plasma para covid-19 após autorização dos EUA”. Agência Brasil, 25 de agosto de 2020, https://agenciabrasil.ebc.com.br/internacional/noticia/2020-08/oms-pede-cautela-com-plasma-para-covid-19-apos-autorizacao-dos-eua.
- Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020 Sep;92(9):1475-1483. doi: 10.1002/jmv.25961. Epub 2020 May 12. PMID: 32356910; PMCID: PMC7267113.
- Rajendran, Karthick, et al. “Convalescent plasma transfusion for the treatment of COVID?19: Systematic review”. Journal of Medical Virology, maio de 2020, p. 10.1002/jmv.25961. PubMed Central, https://doi.org/10.1002/jmv.25961.
- UpToDate. https://www.uptodate.com/contents/covid-19-questions-and-answers?search=terapia%20de%20urgencia%20intensiva%20covi%2019&source=search_result&selectedTitle=5~150&usage_type=default&display_rank=3. Acessado 28 de agosto de 2021.
- UpToDate. https://www.uptodate.com/contents/covid-19-convalescent-plasma-and-hyperimmuneglobulin?search=PLASMA%20COVALESCENTE&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Acessado 28 de agosto de 2021.
- UpToDate. https://www.uptodate.com/contents/the-adaptive-humoral-immune-response?sectionName=PASSIVE%20HUMORAL%20IMMUNITY&search=PLASMA%20COVALESCENTE&topicRef=128321&anchor=H2&source=see_link#H2. Acessado 29 de agosto de 2021.
- Yi?eno?lu TN, Hac?bekiro?lu T, Berber ?, Dal MS, Ba?türk A, Namdaro?lu S, Korkmaz S, Ulas T, Dal T, Erkurt MA, Turgut B, Altunta? F. Convalescent plasma therapy in patients with COVID-19. J Clin Apher. 2020 Aug;35(4):367-373. doi: 10.1002/jca.21806. Epub 2020 Jul 9. PMID: 32643200; PMCID: PMC7361338.
- Yi?eno?lu, Tu?çe Nur, et al. “Convalescent Plasma Therapy in Patients with COVID-19”. Journal of Clinical Apheresis, vol. 35, no 4, 2020, p. 367–73. Wiley Online Library, https://doi.org/10.1002/jca.21806.
